Authors
Latest:
Attention Deficit Hyperactivity DisorderDr, Applebaum explains how to diagnose and treat people with ADHD.
Latest:
MedTech Moments: Episode 28This podcast features an interview with Evan Steele, CEO of SRSsoft, who discusses "meaningful use" and how it might impact a physician's bottom line if he or she purchases an EHR.
Latest:
Statins for the Prevention of Contrast-Induced Acute Kidney InjuryTwo new studies provide much food for thought concerning the use of statins for the prevention of contrast-induced acute kidney injury (CI-AKI).
Latest:
FDA Roundup: Cannabidiol Approved as the First Marijuana-Derived, Purified Drug SubstanceCatch up on this week's biggest headlines in FDA news.
Latest:
Elevated high-density lipoprotein cholesterol and carotid atherosclerosisWe assessed the relationship between high-density lipoprotein (HDL) cholesterol level and carotid plaque progression in 1952 men and women with preexisting carotid atherosclerosis over a period of 7 years. The HDL cholesterol level was inversely related to plaque growth. The plaques that became more echogenic during follow-up had a lower growth rate compared with those that became more echolucent. These findings suggest that HDL cholesterol stabilizes plaques and counteracts their growth by reducing their lipid content and inflammation.
Latest:
The Evolving Nature of Physician Use of Internet-based Communication with PatientsIf there was any remaining question regarding the revolutionary impact of the Internet on communication between physicians and patients, a recent report provides a most provocative answer. In a survey conducted by Manhattan Research, "Physicians in 2012: The Outlook on Health Information Technology", it was noted that 39% of physicians use some form of electronic media such as e-mail, instant messaging, and secure messaging to communicate with their patients.
Latest:
Vemurafenib for the Treatment of Patients with BRAF V600E-Positive Papillary Thyroid CancerResults from a small study show that vemurafenib is an effective and well-tolerated treatment option for patients with BRAF V600E-positive papillary thyroid cancer.
Latest:
Insights from the Psychology of HiringA few insights for job seekers from the other side of the hiring desk.
Latest:
Inflammation and its Effects on Cardiovascular Health Part 1Peter Libby, MD, discusses the science behind inflammation and cardiovascular health.
Latest:
Chronic Obstructive Pulmonary Disease: Diagnosis and TreatmentChronic obstructive pulmonary disease is a leading cause of morbidity and mortality and a considerable drain on health care resources in the industrialized world. In some patients the disease is inherited, but the vast majority of cases are caused by cigarette smoking. Recognizing the signs and symptoms and understanding the disease progression will facilitate a timely diagnosis. Although the disease is incurable, encouraging patients to stop smoking and providing supplemental oxygen can enhance survival. Significant advances in management as outlined by the authors notwithstanding, efforts to reduce the prevalence of cigarette smoking hold the most promise for reducing the disease burden and associated costs.
Latest:
A weighty problemIf only we could do for diabetes what we have done in the past decade for hyperlipidemia.
Latest:
Advancements in Field of Multiple SclerosisJoan Ohayon, registered nurse practitioner, discusses the advancements of research and treatment options in MS.
Latest:
Atrial fibrillation after cardiac surgeryWe assessed preoperative cardiac physiology using echocardiography in patients undergoing cardiac surgery to identify predictors of postoperative atrial fibrillation. Subjects with enlarged left atrial volume had a 5-fold greater risk of postoperative atrial fibrillation, independent of age and other risk factors, than those without enlarged left atrial volume. Left atrial volume appears to be a powerful tool to stratify patients according to risk before surgery and to effectively target preventive therapy.
Latest:
Myth Busted: Young People Do Get Heart DiseaseAt AAPA 2017 in Las Vegas, Jennifer Carlquist PA-C, ER, CAQ said that she believed clinicians are trained in medicine to think heart disease is "an old person's disease," so they don't have it on their radar for the young people (teen years through mid-30s).
Latest:
Solving the IBS RiddleThe goal of IBS management should be to improve overall symptoms, including altered stool frequency and consistency, abdominal pain and discomfort, bloating, and quality of life.
Latest:
FDA Approves Ubrogepant for Acute Migraine in AdultsThe oral CGRP antagonist becomes the first in its class approved for the indication.
Latest:
New Framingham Heart Study global cardiovascular risk instruments: Helping physicians optimize their patients' cardiovascular careWhile most patients are concerned about their risk for myocardial infarction, it is important to remember that the risk factors for death from all cardiovascular diseases, including stroke, peripheral arterial disease, and coronary artery disease, are similar.
Latest:
Principal Study Investigator Discusses Rigel's ITP Therapy ApprovalThe FDA approved fostamatinib disodium hexahydrate (Tavalisse) tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia. RDR discusses with Dr James Bussel.
Latest:
Comprehensive lifestyle modification and blood pressure controlLifestyle recommendations for the prevention and treatment of hypertension include weight loss, reduced sodium intake, increased physical activity, limited alcohol intake, and the Dietary Approaches to Stop Hypertension (DASH) diet. The 18-month results of the Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) randomized clinical trial showed that individuals with prehypertension and stage 1 hypertension can make and sustain many of these lifestyle changes over the long term, thereby reducing their risk of cardiovascular disease.
Latest:
CMSC 2012: Oral Teriflunomide Not Superior to Interferon in Risk of Treatment FailureThe oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.
